A study on adverse drug events of PD-1/PD-L1 inhibitors in lung cancer treatment: a decade-long data mining.

ABSTRACT: PD-1/PD-L1 inhibitors provide new opportunities to reduce global burden of lung cancer. However, adverse drug events (ADEs) pose significant risks to patient health, warranting systematic attention. Data on ADEs associated with PD-1/PD-L1 inhibitors for lung cancer treatment were collected from FDA Adverse Event Reporting System (FAERS) database between January 2014 and June 2023. Logistic regression was used to explore potential factors related to death. Signal mining for ADEs was performed using reporting odds ratio (ROR) and Bayesian Confidence Propagation Neural Network (BCPNN) methods, which revealed toxicity characteristics of these inhibitors among different system organ classes (SOCs) in terms of the number of both ADEs and ADE signals, and the signal strength. Additionally, factor

SUBMITTER: Jia C 

PROVIDER: S-EPMC12518638 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature